SCHEMBL4185022

SCHEMBL4185022

O=C(C=Cc1ccccn1)c1cccnc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.68
CYP1A2 P05177 6/20 0.68
CYP1B1 Q16678 6/20 0.68
CYP3A4 P08684 4/20 0.68
CYP2D6 P10635 4/20 0.68
MAPT P10636 6/20 0.61
ALDH1A1 P00352 4/20 0.61
LMNA P02545 3/20 0.61
KMT2A Q03164 2/20 0.61
HPGD P15428 1/20 0.61
KDM4E B2RXH2 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
APP P05067 1/20 0.56
GSK3B P49841 1/20 0.56
HSP90AA1 P07900 1/20 0.55
MEN1 O00255 1/20 0.55
TUBB4A P04350 1/20 0.55
TUBB P07437 1/20 0.55
TUBA3C P0DPH7 1/20 0.55
TUBA1B P68363 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664956 1.00 CYP1A1 (0.68) CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6
Wr-190433 SCHEMBL6180067 0.85 TUBB4A (0.66) CYP1B1CYP3A4MAPTALDH1A1LMNA
Wr-190433 SCHEMBL30880222 0.85 TUBB4A (0.66) CYP1B1CYP3A4MAPTALDH1A1LMNA
Wr-190433 SCHEMBL29870441 0.85 TUBB4A (0.66) CYP1B1CYP3A4MAPTALDH1A1LMNA
Wr-190433 SCHEMBL977482 0.85 TUBB4A (0.66) CYP1B1CYP3A4MAPTALDH1A1LMNA
SCHEMBL15882450 0.83 TUBB4A (0.72) CYP1B1MAPTALDH1A1LMNAKMT2A
SCHEMBL15882451 0.83 TUBB4A (0.72) CYP1B1MAPTALDH1A1LMNAKMT2A
SCHEMBL10376888 0.81 HSP90AA1 (0.55) CYP1B1MAPTALDH1A1LMNAKMT2A
SCHEMBL10376889 0.81 HSP90AA1 (0.55) CYP1B1MAPTALDH1A1LMNAKMT2A
SCHEMBL9503680 0.81 CYP1B1 (1.00) CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CYP1A1 339/4885CYP1A2 616/4885CYP1B1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.